\u201cAt Pfizer, we address some of the most urgent challenges in infectious diseases, delivering vaccines and anti-infective therapies that protect and treat people today while pursuing innovations to expand their impact in the future. Our data at IDWeek 2026 reflects this commitment, with real-world and clinical data across our portfolio as well as important clinical milestones for our next-generation pediatric pneumococcal vaccine candidate and registrational Lyme vaccine candidate. Through these efforts, we are translating scientific advancements into meaningful benefits for communities around the world.\u201d<\/i><\/p>\n
\n\u2014 Annaliesa Anderson, Ph.D., Senior Vice President and Chief Vaccines Officer, Pfizer<\/b><\/p>\n
Key Highlights of Pfizer\u2019s Presence at IDWeek 2026<\/b><\/p>\n
Advancing Next-Generation Vaccines Across Infectious Diseases<\/i><\/b><\/p>\n Expanding Evidence of Vaccine Impact in Practice<\/i><\/b><\/p>\n IDWeek Presence Reinforces Pfizer\u2019s Commitment to Addressing the Threat of Infectious Diseases<\/b><\/p>\n \nAs infectious diseases remain a persistent cause of illness and death worldwide, Pfizer is focused on generating the evidence needed to bring effective vaccines andanti-infective therapies to as many people as possible. Our data at IDWeek reflect that strategy, concentrating innovation in disease areas with the greatest opportunity to impact public health globally, whether through large at-risk populations, the potential for longer-lasting protection, or both. Highlights include emerging data from late-stage investigational programs advancing next-generation vaccines, new analyses supporting established vaccines as standards of care, real-world evidence that deepens understanding of vaccine effectiveness across diverse populations, and several studies surrounding our current and investigational COVID-19 anti-infective therapies.<\/p>\n Detailed Presentation Information<\/b><\/p>\n \nInformation on oral presentations led by Pfizer and its collaborators can be found in the table below. A complete list of presentations is available here<\/a>.<\/p>\n\n
\n
(Presentation Title: Immunogenicity of a 25-valent pneumococcal coverage vaccine compared with PCV20 in healthy infants: Evaluating a candidate to improve pneumococcal coverage in a Phase 2 trial)<\/p>\n<\/li>\n
\n
(Presentation Title: Safety and immunogenicity of LP.8.1-adapted BNT162b2 COVID-19 vaccine in children 5\u201311 years of age)<\/p>\n<\/li>\n
\n
(Presentation Title: Efficacy and safety of the LB6V Lyme disease vaccine candidate: Results from a Phase 3 study in participants \u22655 years of age)<\/p>\n<\/li>\n<\/ul>\n\n
\n
(Presentation Title: First available vaccine effectiveness of bivalent RSVpreF against laboratory-confirmed RSV infection in nursing home residents through 3 seasons after vaccination \u2014 2025-2026)<\/p>\n<\/li>\n
\n
(Presentation Title: Maternal RSVpreF vaccine effectiveness against respiratory syncytial virus (RSV) in hospitalized infants by age, vaccination characteristics, and RSV subtype: A multicenter test-negative design study in Australia, 2025-2026 (STREETON Study))<\/p>\n<\/li>\n
\n
(Presentation Title: 20-valent pneumococcal conjugate vaccine: Impact and effectiveness against all-cause outcomes among the general population of US older adults by age group, regardless of prior pneumococcal vaccine history)<\/p>\n<\/li>\n
\n
(Presentation Title: Long-term seroprotection following two-dose MenABCWY: Modeling supports benefits of extended dosing intervals)<\/p>\n<\/li>\n<\/ul>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20261014474581\/en\/1045874\/3\/Pfizer_Logo_Color_RGB_APPROVED.jpg\"){kind=logo}
<\/td>\n<\/tr>\n